Date Filed | Type | Description |
01/24/2023 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Granted 35,938 options to buy
@ $0.4688, valued at
$16.8k
|
|
10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/27/2022 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Bought 18,867 shares
@ $0.55, valued at
$10.4k
|
|
06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/10/2022 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Bought 1,000 shares
@ $4.92, valued at
$4.9k
Bought 1,000 shares
@ $4.75, valued at
$4.8k
|
|
02/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/31/2022 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Bought 5,000 shares
@ $5.303, valued at
$26.5k
|
|
10/12/2021 |
4
| Ehrlich Christopher B (CEO and Secretary) has filed a Form 4 on PHOENIX BIOTECH ACQUISITION CORP.
Txns:
| Acquired 36,733 shares
@ $10, valued at
$367.3k
Disposed of 82,875 options to buy
@ $0 Acquired 18,366 warrants
@ $11.5, valued at
$211.2k
|
|
10/08/2021 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on eFFECTOR Therapeutics, Inc.
Txns:
| Granted 40,000 options to buy
@ $11.36, valued at
$454.4k
|
|
10/05/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
08/27/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/14/2021 |
4
| Ehrlich Christopher B (See Remarks) has filed a Form 4 on Locust Walk Acquisition Corp.
Txns:
| Disposed of 23,750 options to buy
@ $0 |
|
01/07/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/11/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
03/05/2013 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on BIOMIMETIC THERAPEUTICS, INC.
Txns:
| Disposed/sold 1,250 shares
@ $0 Disposed/sold 941,177 shares
@ $0 Disposed/sold 857,692 shares
@ $0 Disposed/sold 6,846 shares
@ $0 Disposed/sold 24,538 shares
@ $0 Disposed/sold 5,831 options to buy
@ $17.09, valued at
$99.7k
Disposed/sold 8,840 options to buy
@ $11.64, valued at
$102.9k
|
|
01/08/2013 |
4
| Ehrlich Christopher B (10% Owner) has filed a Form 4 on Transcept Pharmaceuticals Inc
Txns:
| Granted 13,500 options to buy
@ $5.4, valued at
$72.9k
|
|
07/05/2012 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/27/2012 |
3
| INTERWEST PARTNERS X LP (10% Owner) has filed a Form 3 on TESARO, Inc. |
01/25/2012 |
4
| Ehrlich Christopher B (10% Owner) has filed a Form 4 on Transcept Pharmaceuticals Inc
Txns:
| Granted 7,000 options to buy
@ $8.18, valued at
$57.3k
|
|
09/22/2011 |
4
| Ehrlich Christopher B (10% Owner) has filed a Form 4 on Transcept Pharmaceuticals Inc
Txns:
| Bought 514,848 shares
@ $6.585, valued at
$3.4M
Bought 217,228 shares
@ $7.2418, valued at
$1.6M
|
|
01/27/2011 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/10/2010 |
4
| InterWest Partners IX, LP (10% Owner) has filed a Form 4 on Trius Therapeutics Inc
Txns:
| Converted 1,576,814 shares
@ $0 Converted 744,496 shares
@ $4.38, valued at
$3.3M
Bought 1,227,333 shares
@ $5, valued at
$6.1M
Converted 9,090,910 convertible preferred
@ $0 Converted 4,469,697 convertible preferred
@ $0 |
|
08/02/2010 |
3
| InterWest Partners IX, LP (10% Owner) has filed a Form 3 on Trius Therapeutics Inc |
02/04/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
01/19/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
04/08/2009 |
4
| Form 4 -- Statement of changes in beneficial ownership of securities |
02/03/2009 |
4
| Ehrlich Christopher B (Director) has filed a Form 4 on Transcept Pharmaceuticals Inc |
02/03/2009 |
3
| Ehrlich Christopher B (Director) has filed a Form 3 on Transcept Pharmaceuticals Inc |